• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

kanta.subbarao@unimelb.edu.au

Credentials


Position
Honorary (Professorial Fellow)
Department of Microbiology and Immunology
ORCID

0000-0003-1713-3056

Prof Kanta Subbarao

Honorary (Professorial Fellow)
Department of Microbiology and Immunology

426 Scholarly works
68 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Preclinical development of a cross-protective β-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59
    DOI: 10.1038/s41541-025-01355-y
  • 2026

    Journal article

    Room-return ventilation and N95 respirator policies for reducing airborne pathogen exposure on hospital wards
    DOI: 10.1016/j.jhin.2026.05.023
  • 2026

    Journal article

    Delivery of monoclonal antibodies using mRNA lipid nanoparticles confers protection against SARS-CoV-2 and influenza
    DOI: 10.1016/j.omtn.2026.102873
  • 2026

    Journal article

    Influenza vaccine responses differ between young children previously exposed to influenza antigens via infection versus vaccination.
    DOI: 10.1038/s43856-026-01610-w
  • 2024

    Research grants (international)

    (CRA With Melbourne Health and Aus Bio) Development of a Novel Long Acting Pan-Influenza Antiviral Drug
  • 2021

    Research grants (ARC, NHMRC, MRFF)

    Chimeric Next Generation COVID Vaccines
  • 2020

    Research grants (ARC, NHMRC, MRFF)

    Translating Virus Biology and Host Immunity for Influenza Control
Kanta Subbarao

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia
    DOI: 10.1016/j.jinf.2026.106727
  • 2026

    Journal article

    Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18–55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Trial
    DOI: 10.1093/infdis/jiaf568
  • 2026

    Journal article

    Nomenclature for Tracking of Genetic Variation of Seasonal Influenza Viruses
    DOI: 10.1111/irv.70230
  • 2026

    Journal article

    Antibody responses following COVID-19 vaccination and breakthrough infections in naïve and convalescent individuals suggest imprinting to the ancestral strain of SARS-CoV-2
    DOI: 10.1128/mbio.03221-25
  • 2026

    Journal article

    SARS-CoV-2 infection patterns and immune responses by fourth-dose COVID-19 vaccination status
    DOI: 10.1016/j.anzjph.2026.100489
  • 2026

    Journal article

    PICOBOO: the immunogenicity of COVID-19 booster vaccines in individuals >12 years old
    DOI: 10.1016/j.anzjph.2026.100543

RECENT PROJECTS

  • 2024

    Research contracts (non-grants)

    Leyden SARS2/NL63 Block Contract - Assessment of the Antiviral Agents Against SARS-CoV-2 and Human Coronavirus NL63
  • 2025

    Research grants (other domestic)

    Developing CRISPR Cas13 Antiviral Therapeutics for Respiratory Pathogens of Pandemic Potential

Acknowledgement of Country

We acknowledge Aboriginal and Torres Strait Islander people as the Traditional Owners of the unceded lands on which we work, learn and live. We pay respect to Elders past, present and future, and acknowledge the importance of Indigenous knowledge in the Academy.

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224